A PYMNTS Company

Judge Narrows Antitrust Case Against Teva Over Gilead HIV Drugs

By  |  January 16, 2022

Teva Pharmaceutical Industries succeeded in scaling back its potential antitrust exposure for allegedly helping delay generic versions of Gilead Sciences’s blockbuster HIV drugs, when a federal judge in San Francisco ruled that some claims against Teva were filed too late.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to Bloomberl Law, Judge Edward M. Chen narrowed the allegations against Teva, one of several pharmaceutical companies accused of taking a “reverse payment” from Gilead to shelve its generic version of Truvada as part of a settlement resolving patent infringement litigation.

    “Reverse payment” settlements—so called because they involve concessions from a patent plaintiff to a defendant, rather than in the usual.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.